(Q50304209)

2 March 2018

title

Risperidone in the treatment of pervasive developmental disorder. (English)

1 reference

2 March 2018

pervasive developmental disorder

main subject

0 references

1 reference

Purdon SE

1

1 reference

2 March 2018

Lit W

series ordinal

2

1 reference

2 March 2018

Labelle A

series ordinal

3

1 reference

2 March 2018

Jones BD

series ordinal

4

1 reference

2 March 2018

language of work or name

English

0 references

publication date

1 September 1994

1 reference

2 March 2018

Canadian Journal of Psychiatry

published in

1 reference

2 March 2018

volume

39

1 reference

2 March 2018

issue

7

1 reference

2 March 2018

page(s)

400-405

1 reference

2 March 2018

Outcome in autism and autistic-like conditions

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Comparisons of DSM-III defined pervasive developmental disorders in North Dakota children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Review of fenfluramine in the treatment of the developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

The "autistic psychopaths" in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Asperger's syndrome: a clinical account

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Autistic children who become schizophrenic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Infantile autism and affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Asperger's syndrome and recurrent psychosis--a case study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

A vote for Asperger's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Effects of L-dopa in autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Increased Blood Serotonin and Platelets in Early Infantile Autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Examination of circadian rhythmicity of blood serotonin and platelets in autistic and non-autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Uptake and efflux of serotonin from platelets of autistic and nonautistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Reassessment of elevated serotonin levels in blood platelets in early infantile autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Hyperserotonemia and amine metabolites in autistic and retarded children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Blood Serotonin and Free Tryptophan Concentration in Autistic Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Whole blood serotonin in autistic and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Platelet serotonin, a possible marker for familial autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Side effects of fenfluramine in autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

Neurotoxic action of halogenated amphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379403900703

10.1177/070674379403900703

21 January 2018

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018